All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Prima Biomed Ltd., of Sydney, said it will receive an undisclosed clinical milestone payment from partner Novartis AG, of Basel, Switzerland, related to its phase I IMP701 LAG-3 antibody, in testing against cancer.